|
|
| | Rovelizumab Basic information |
| Product Name: | Rovelizumab | | Synonyms: | Research Grade Rovelizumab(DHC13102);Research Grade Rovelizumab | | CAS: | 339086-79-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Rovelizumab Structure]() |
| | Rovelizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Rovelizumab Usage And Synthesis |
| Uses | Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke[1]. | | References | [1] Jones R. Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6. PMID:16100700
[2] Qualls JE, et al. A double agent in cancer: stopping macrophages wounds tumors. Nat Med. 2010 Aug;16(8):863-4. DOI:10.1038/nm0810-863 |
| | Rovelizumab Preparation Products And Raw materials |
|